Cystatin C Lab Test: Normal Range vs. Functional Optimal Levels

What Is Cystatin C and Why Does It Matter?

Cystatin C is a small protein produced by nucleated cells. It passes through the kidney's filtering units and is then taken up and broken down in proximal tubules. Its concentration in blood generally rises as filtration falls [1,2].

A concentration is a laboratory measurement; estimated glomerular filtration rate, or eGFR, is a calculation. Adult cystatin C equations also use age and sex. These inputs help explain why one concentration cannot be assigned the same kidney-function category in every person [4,6].

Cystatin C is less dependent on muscle mass than creatinine, which can make it useful when body composition complicates a creatinine result. It still has non-filtration influences. It is an additional marker, rather than a direct measurement of GFR or a universally superior replacement for creatinine [1,5].

Inker and colleagues' 2021 validation compared estimates with measured GFR in 4,050 participants. Equations combining creatinine and cystatin C without race were more accurate than the new creatinine-only equation [3]. The commonly used cystatin-C-only equation is from 2012; the 2021 update should not be described as introducing a new cystatin-C-only formula [4,6].

A 2013 meta-analysis included 90,750 general-population participants and 2,960 participants with CKD. Reclassification using cystatin C was associated with different mortality and kidney-failure risks. That finding supports better risk assessment; it does not guarantee that a fixed fraction of patients will move from stage 3a to stage 2 [8].

Standard "Normal" Range vs. Functionally Optimal

Use the interval printed on the report. Mayo Clinic Laboratories currently lists cystatin C intervals of 0.63 to 1.03 mg/L for adults aged 18 to 49 and 0.67 to 1.21 mg/L for adults aged 50 and older. These examples describe that laboratory's test, not every U.S. laboratory [2].

A reference interval is not a treatment target. Neither those laboratory intervals nor the cited eGFR equations establish a universal "functionally optimal" concentration of 0.60 to 0.80 mg/L. Age, sex, the equation and related findings matter more than placing everyone inside a narrow concentration band [2,4,6].

A practical framework for clinical interpretation:

The combined estimate is particularly useful near a decision boundary. KDIGO 2024 recommends creatinine-based estimation in adults at risk for CKD and using the combined estimate for the GFR category when cystatin C is available [7]. This recommendation is different from requiring every healthy adult to reach one cystatin C concentration.

Why Creatinine Alone Can Be Misleading

Creatinine reflects muscle metabolism as well as kidney clearance. Low muscle mass can make a creatinine result look reassuring despite reduced filtration; unusually high muscle mass can push it in the other direction. Diet and some medicines also influence creatinine [1,4].

The 2011 Peralta study followed 26,643 adults and evaluated creatinine, cystatin C and urine albumin together. Adding the markers improved classification of mortality and end-stage kidney disease risk. It was not a 2012 trial in adults over 70 demonstrating a specific 9.2-versus-2.1 mL/min estimation bias [9].

Cystatin C is not completely independent of sex, age or health conditions. Stevens and colleagues examined 3,418 people using measured GFR and found associations with factors including diabetes, inflammatory markers, age and sex even after accounting for filtration [5].

Thyroid disease is another important influence. A 22-person study found cystatin C lower during hypothyroidism and higher during hyperthyroidism, with changes after thyroid treatment. Creatinine moved in the opposite direction. Hyperthyroidism should therefore not be presented as a routine explanation for low cystatin C [10].

Medicines that change creatinine secretion and conditions that influence cystatin C production can create different estimates. The combination can reduce the influence of either marker, but a difficult result may still require measured GFR when a precise value changes a treatment decision [1,4,24].

How to Interpret a High Cystatin C Result

A high concentration can be consistent with reduced filtration, but values above 1.00 or 1.20 mg/L do not map to one fixed eGFR for every adult. Check the age-appropriate laboratory interval, the reported equation and the creatinine result [2,4,6].

CKD assessment also includes duration and markers of kidney damage. An eGFR below 60 mL/min/1.73 m² or other qualifying abnormalities must generally be present for at least three months to establish chronic disease. A new abnormal result can have an acute explanation; one measurement cannot establish chronicity [7].

Cystatin C also carries prognostic information. In a study of 4,637 older adults, the highest quintile was associated with greater cardiovascular mortality risk than the two lowest quintiles combined: adjusted hazard ratio 2.27. This was an observational association in that population, not proof that lowering the concentration itself prevents an event [11].

A useful follow-up sequence is to review prior results, compare creatinine and cystatin C estimates, assess urine albumin, and consider thyroid function, inflammation and medicines. The repeat-testing interval depends on whether the concern is an acute change or a stable chronic pattern [5,7,10].

Referral depends on the broader findings. National Kidney Foundation materials identify factors such as eGFR below 30, severe albuminuria, an uncertain cause or acute kidney injury. An eGFR below 60 does not automatically require the same referral decision for every adult [23].

What a Low Cystatin C Means

A lower cystatin C concentration generally corresponds to a higher estimated filtration rate, but a value below 0.55 mg/L does not by itself diagnose hyperfiltration. The appropriate reference interval and equation remain relevant [2,6].

Hyperfiltration occurs in several settings, including diabetes and obesity, and there is no single agreed definition across all populations. A review by Helal and colleagues describes the underlying kidney hemodynamics and their variation with the clinical setting [12].

Non-filtration influences can also lower the concentration. In the thyroid study, hypothyroidism was associated with lower cystatin C before treatment. A low value should therefore be interpreted with the clinical history and related tests, rather than attributed automatically to hyperthyroidism or exceptionally healthy kidneys [10].

Evidence-Based Strategies to Improve Cystatin C Levels

The treatment goal is better kidney health and relevant clinical outcomes, rather than moving an isolated biomarker into an unsupported optimal band. The evidence for interventions depends on the condition being treated.

Blood pressure control. SPRINT randomized 9,361 higher-risk adults without diabetes to intensive or standard blood-pressure treatment. Its primary benefit was fewer cardiovascular events, not the claimed 15% reduction in a kidney composite. The study does not establish one cystatin C target or one blood-pressure goal for all readers [13].

SGLT2 inhibitors. CREDENCE studied 4,401 people with type 2 diabetes and albuminuric CKD. Canagliflozin reduced its primary composite by 30%; that composite included kidney outcomes and death from kidney or cardiovascular causes [14]. DAPA-CKD enrolled 4,304 participants with CKD, including people without diabetes, and found fewer primary composite events with dapagliflozin. These trial populations and outcomes should not be converted into a prescription rule based on cystatin C alone [15].

Glycemic management. UKPDS 35 was observational. Its 21% figure per one-percentage-point lower HbA1c concerned any diabetes-related endpoint, rather than a specifically measured 21% reduction in CKD progression [16]. In FLOW, 3,533 participants with type 2 diabetes and CKD received semaglutide 1.0 mg weekly or placebo. The primary major-kidney-disease composite, which included cardiovascular death, was reduced by 24%. This is evidence for that treatment and population, rather than a guarantee for every GLP-1 medicine or every elevated cystatin C result [17].

Dietary protein moderation. MDRD tested different protein intakes in people with established renal disease. The projected three-year GFR decline in its moderate-disease study did not differ significantly between diet groups; the results were more nuanced than a guaranteed 1.15 mL/min yearly benefit [18]. Dietary targets depend on kidney stage and nutritional needs. They should not be derived solely from a cystatin C concentration.

Hydration and NSAID avoidance. Medication combinations matter. Lapi and colleagues studied 487,372 antihypertensive users. Combining an NSAID with both a diuretic and an ACE inhibitor or ARB was associated with acute kidney injury, with a rate ratio of 1.31. This was not a study showing that all NSAID users had a 32% higher chance of a five-year eGFR decline [19]. Hydration and medication assessment belong in the clinical context; neither establishes a predictable cystatin C improvement.

Weight management. STEP 1 demonstrated weight reduction with semaglutide 2.4 mg in 1,961 adults without diabetes. Its primary outcomes were weight change and achieving at least 5% weight loss. That report does not establish the claimed 5.3 mL/min kidney-function improvement based on the amount of weight lost [20]. Kidney-specific treatment evidence should be distinguished from a weight-loss trial, such as the separate FLOW population described above [17].

When to Request a Cystatin C Test

Testing is most useful when an additional estimate can resolve uncertainty or change a decision. Examples include unusually high or low muscle mass and a creatinine-based result close to a drug-dosing or other clinical threshold [4,22,24].

Guidelines differ. The National Kidney Foundation describes confirmatory use when creatinine-based eGFR is 45 to 59 with urine albumin below 30 mg/g, and when creatinine may be unreliable near a decision point [22]. NICE NG203 removed the older 2014 cystatin C diagnostic recommendations because the committee considered the evidence for equation accuracy insufficient. The superseded CG182 recommendation should not be described as current NICE guidance [21].

Monitoring is based on the condition and whether the result will inform care. An annual cystatin C test is not established as a universal requirement for everyone taking TRT, a GLP-1 medicine or metformin. National Kidney Foundation materials recommend at least annual eGFR and urine albumin assessment for people at high CKD risk, with follow-up adapted to findings [23].

Test prices, insurance coverage and turnaround times vary by laboratory and plan. The testing laboratory's current quote and the plan's benefits are the relevant sources for a specific test, rather than a universal $30-to-$80 estimate or a coverage promise tied to a diagnosis code.

Cystatin C vs. Creatinine: A Direct Comparison

The combined equation generally performs better than either marker alone, but an estimate still has uncertainty. NIDDK reports P30 values of approximately 90% for the 2021 combined equation. P30 means the percentage of estimates within 30% of measured GFR; it is not a claim that each individual's result is 90% accurate [3,4]. Trends, urine albumin and the clinical decision remain part of interpretation.